FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899403225> ?p ?o ?g. }

• W2899403225 endingPage "2512" @default.
• W2899403225 startingPage "2503" @default.
• W2899403225 abstract "Abstract Purpose: In chronic lymphocytic leukemia (CLL), disease progression associates with surface IgM (sIgM) levels and signaling capacity. These are variably downmodulated in vivo and recover in vitro, suggesting a reversible influence of tissue-located antigen. Therapeutic targeting of sIgM function via ibrutinib, an inhibitor of Bruton tyrosine kinase (BTK), causes inhibition and tumor cell redistribution into the blood, with significant clinical benefit. Circulating CLL cells persist in an inhibited state, offering a tool to investigate the effects of drug on BTK-inhibited sIgM. Experimental Design: We investigated the consequences of ibrutinib therapy on levels and function of sIgM in circulating leukemic cells of patients with CLL. Results: At week 1, there was a significant increase of sIgM expression (64% increase from pretherapy) on CLL cells either recently released from tissue or persisting in blood. In contrast, surface IgD (sIgD) and a range of other receptors did not change. SIgM levels remained higher than pretherapy in the following 3 months despite gradual cell size reduction and ongoing autophagy and apoptotic activity. Conversely, IgD and other receptors did not increase and gradually declined. Recovered sIgM was fully N-glycosylated, another feature of escape from antigen, and expression did not increase further during culture in vitro. The sIgM was fully capable of mediating phosphorylation of SYK, which lies upstream of BTK in the B-cell receptor pathway. Conclusions: This specific IgM increase in patients underpins the key role of tissue-based engagement with antigen in CLL, confirms the inhibitory action of ibrutinib, and reveals dynamic adaptability of CLL cells to precision monotherapy. See related commentary by Burger, p. 2372" @default.
• W2899403225 created "2018-11-09" @default.
• W2899403225 creator A5003829195 @default.
• W2899403225 creator A5007119947 @default.
• W2899403225 creator A5013236194 @default.
• W2899403225 creator A5015977621 @default.
• W2899403225 creator A5021027711 @default.
• W2899403225 creator A5042489872 @default.
• W2899403225 creator A5045582236 @default.
• W2899403225 creator A5047140412 @default.
• W2899403225 creator A5073100802 @default.
• W2899403225 creator A5078295579 @default.
• W2899403225 date "2019-04-15" @default.
• W2899403225 modified "2023-09-24" @default.
• W2899403225 title "Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients" @default.
• W2899403225 cites W1243376384 @default.
• W2899403225 cites W1429374962 @default.
• W2899403225 cites W1524525339 @default.
• W2899403225 cites W1686167184 @default.
• W2899403225 cites W1851200632 @default.
• W2899403225 cites W1966949480 @default.
• W2899403225 cites W1969953749 @default.
• W2899403225 cites W1971163722 @default.
• W2899403225 cites W1971818445 @default.
• W2899403225 cites W1975673932 @default.
• W2899403225 cites W1975783419 @default.
• W2899403225 cites W1990986028 @default.
• W2899403225 cites W1991988533 @default.
• W2899403225 cites W1998068719 @default.
• W2899403225 cites W2009414302 @default.
• W2899403225 cites W2021615173 @default.
• W2899403225 cites W2056807976 @default.
• W2899403225 cites W2064381013 @default.
• W2899403225 cites W2064583052 @default.
• W2899403225 cites W2065338378 @default.
• W2899403225 cites W2066030565 @default.
• W2899403225 cites W2078906337 @default.
• W2899403225 cites W2091664866 @default.
• W2899403225 cites W2094052642 @default.
• W2899403225 cites W2113475715 @default.
• W2899403225 cites W2128312303 @default.
• W2899403225 cites W2131199230 @default.
• W2899403225 cites W2136813292 @default.
• W2899403225 cites W2142160913 @default.
• W2899403225 cites W2154360891 @default.
• W2899403225 cites W2156834005 @default.
• W2899403225 cites W2157740207 @default.
• W2899403225 cites W2172019913 @default.
• W2899403225 cites W2172718055 @default.
• W2899403225 cites W2178037583 @default.
• W2899403225 cites W2274569534 @default.
• W2899403225 cites W2316244721 @default.
• W2899403225 cites W2318933236 @default.
• W2899403225 cites W2403449504 @default.
• W2899403225 cites W2428539785 @default.
• W2899403225 cites W2482579995 @default.
• W2899403225 cites W2513601254 @default.
• W2899403225 cites W2623503441 @default.
• W2899403225 cites W2756143144 @default.
• W2899403225 cites W2778605238 @default.
• W2899403225 cites W2781624645 @default.
• W2899403225 cites W9699790 @default.
• W2899403225 doi "https://doi.org/10.1158/1078-0432.ccr-18-1286" @default.
• W2899403225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30373751" @default.
• W2899403225 hasPublicationYear "2019" @default.
• W2899403225 type Work @default.
• W2899403225 sameAs 2899403225 @default.
• W2899403225 citedByCount "21" @default.
• W2899403225 countsByYear W28994032252019 @default.
• W2899403225 countsByYear W28994032252020 @default.
• W2899403225 countsByYear W28994032252021 @default.
• W2899403225 countsByYear W28994032252022 @default.
• W2899403225 countsByYear W28994032252023 @default.
• W2899403225 crossrefType "journal-article" @default.
• W2899403225 hasAuthorship W2899403225A5003829195 @default.
• W2899403225 hasAuthorship W2899403225A5007119947 @default.
• W2899403225 hasAuthorship W2899403225A5013236194 @default.
• W2899403225 hasAuthorship W2899403225A5015977621 @default.
• W2899403225 hasAuthorship W2899403225A5021027711 @default.
• W2899403225 hasAuthorship W2899403225A5042489872 @default.
• W2899403225 hasAuthorship W2899403225A5045582236 @default.
• W2899403225 hasAuthorship W2899403225A5047140412 @default.
• W2899403225 hasAuthorship W2899403225A5073100802 @default.
• W2899403225 hasAuthorship W2899403225A5078295579 @default.
• W2899403225 hasBestOaLocation W28994032251 @default.
• W2899403225 hasConcept C126322002 @default.
• W2899403225 hasConcept C147483822 @default.
• W2899403225 hasConcept C157695867 @default.
• W2899403225 hasConcept C159654299 @default.
• W2899403225 hasConcept C170493617 @default.
• W2899403225 hasConcept C203014093 @default.
• W2899403225 hasConcept C2777938653 @default.
• W2899403225 hasConcept C2778453870 @default.
• W2899403225 hasConcept C2778461978 @default.
• W2899403225 hasConcept C2779878957 @default.
• W2899403225 hasConcept C35174551 @default.
• W2899403225 hasConcept C42362537 @default.
• W2899403225 hasConcept C48010095 @default.

• next